The SARATOGA study is evaluating the safety & effectiveness of lifileucel, a tumor-infiltrating lymphocytetherapy for adults w/ previously treated advanced soft tissue sarcoma, including dedifferentiated liposarcoma. https://t.co/Dl9TmkAO44 #dedifferentiated#liposarcoma#DDLPS
Final Phase 2, lifileucel + pembrolizumab, data explore earlier use of #TILtherapy in frontline melanoma at #ESMO26.
Details here: https://t.co/H5XM5gJ3Hm
Heading to #ESMO26 this weekend? Stop by the Iovance booth to meet our team and learn more about our commitment to advancing cell therapy for people living with cancer. #Iovance#TILTherapy
Iovance is at #CGTS2026 in NYC 🗽today. Two of our colleagues are joining discussions on cell therapy access, quality, and policy. Thank you @AVBCC for convening the conversation. #CellTherapy#PatientAccess
Madrid, here we come! 🇪🇸 Iovance’s 5 abstracts at #ESMO26 (Oct 23–27) showcase the TIL platform, including 2 orals in frontline advanced melanoma 🔬 and refractory soft tissue sarcomas 🧬 Details here: https://t.co/KcexlTTiTN
We’re exhibiting at JADPRO Live 2026. Join us, along with over 1,600 nurse practitioners, physician assistants, clinical nurse specialists, and additional health-care professionals to discuss the innovations in cancer care. Stop by booth #333. #JADPROLive#Celltherapy
Proud Silver Sponsor of #CGMesa26 ☀️🌵Grateful to @alliancerm for bringing the cell & gene therapy community together in Phoenix. Until next year!👏
#CellAndGeneTherapy#CMC
Congratulations to Fred Vogt, PhD, JD, Interim President and CEO of Iovance, on receiving AVBCC’s inaugural Global Cancer Research & Innovation Award, recognizing his contributions to advancing innovation in oncology. Learn more: https://t.co/QItY5YJeOJ
#AVBCC#Celltherapy
We’re pleased to welcome Noah Berkowitz, M.D., Ph.D., as our Chief Medical Officer. He will lead our global drug development efforts as we continue advancing the Iovance TIL platform across multiple solid tumor cancers. Learn more: https://t.co/eFLrEx9mmf
#CellTherapy
Today we raised our FY2026 total revenue guidance to $410–$420M, driven by strong demand for Amtagvi® and Proleukin®. The midpoint is up $55M from the prior $350–$370M range and implies ~60% annual revenue growth. Full release: https://t.co/JOrdC1C11w
This #WorldLungDay, we’re recognizing the continued need for innovation. At Iovance, we're exploring the potential of multiple TIL therapy approaches in metastatic non-small cell lung cancer. Learn more: https://t.co/gy5EgXjbfB
Cancer research turns unanswered questions into evidence, and evidence into new possibilities for patients. Today, we recognize the researchers, clinicians, patients, and caregivers who make that progress possible. #WorldCancerResearchDay#CellTherapy#CancerResearch
Today, our SVP Global Access, Operations & Proleukin, Anne Brooks, joins @BioBuzz for "The Convergence of Life Sciences & Healthcare Delivery" — a panel on patient access, cell & gene therapy, and AI. #CellTherapy#CGT#PatientAccess
On Saturday, September 26, Team Iovance Bay Area will join @AIMatMelanoma's 8th Annual Steps Against Melanoma Walk at Little Marina Green in San Francisco: https://t.co/p0ykLnxIZP
#StepsAgainstMelanoma#AIMatMelanoma
Miles matter.💙Our team walked NYC this Saturday for @CureMelanoma's Miles for Melanoma 5K, standing with the patients, families & advocates who inspire this work. Thank you, MRF! #MilesForMelanoma#MelanomaAwareness
Join Iovance today at 11:00 AM ET as Brian Gastman, MD, and Corleen Roche participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference.
Watch live or access the replay: https://t.co/qIHM4YRb5T
#Iovance#HealthcareConference
Cell therapy doesn't move forward without people — showing up, solving problems, pushing boundaries every single day. This Labor Day, we recognize every Iovance team member making it happen for patients. You are the reason.💙#AdvancingIO#LaborDay